Zhejiang Huahai Pharmaceutical (SHA:600521) received tariff refunds worth $14.2 million through its subsidiary ScieGen Health USA, according to a Shanghai bourse filing on Thursday.
The tariff refunds came after the U.S. Supreme Court ruled that the U.S. government's tariff measures were invalid and the amount should be refunded to importers.
The refunds are expected to raise the pharmaceutical company's net profit for the year by 96.9 million yuan.